Drug Profile
Research programme: androgen receptor antagonists - Janssen Research & Development
Alternative Names: SARD programme - Aragon PharmaceuticalsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of California
- Developer Janssen Research & Development
- Class Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Prostate-cancer(Hormone refractory) in USA (PO)
- 19 Aug 2013 Aragon Pharmaceuticals has been acquired and merged into Johnson & Johnson
- 01 Oct 2012 Early research in Prostate cancer (hormone refractory) is ongoing in USA